Comment on CMS-2026-1256-0002

Summary: Cordis, a medical technology manufacturer, opposes the proposed elimination of the Alternative Pathway for the New Technology Add-on Payment (NTAP) Transitional Pass Through (TPT) programs. They argue that the change creates uncertainty for manufacturers, risks limiting patient access to innovative technologies, and request that CMS delay implementation or limit eligibility to FDA Premarket Approval (PMA) technologies.